Professional
Added to YB: 2024-10-22
Pitch date: 2024-09-30
REGN [bullish]
Regeneron Pharmaceuticals, Inc.
-29.28%
current return
Author Info
No bio for this author
Company Info
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Market Cap
$80.0B
Pitch Price
$1.0K
Price Target
N/A
Dividend
0.45%
EV/EBITDA
14.60
P/E
18.76
EV/Sales
4.49
Sector
Biotechnology
Category
growth
Baron Health Care Fund New Position: Regeneron Pharmaceuticals, Inc.
REGN: Biopharma leader w/ blockbusters Eylea/Eylea HD (retinal) & Dupixent (immunological). Eylea facing patent expiry, but HD version & Dupixent growing. 35+ pipeline candidates incl. food allergy, cancer, blood clot prevention. Strong R&D track record suggests pipeline success, driving potential upside.
Read full article (1 min)